2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, CHIP, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

3516 Epcoritamab retains robust cytotoxic activity in the setting of MS4A1 5′-UTR splice variant V1 with markedly reduced CD20 protein levels

Devika Ashok, Melih Acar, PhD2, Robert E Kupp3, Bill E Goodheart4, Angshumala Goswami5, Kevin Zhao6, Tabrez Mohammad, PhD7, Andrew J Steele, PhD8, Edith Szafer Glusman, PhD9, PK Epling-Burnette, PhD, PharmD10
1 AbbVie Inc., North Chicago, United States
2 AbbVie Inc., North Chicago, United States
3 AbbVie Inc., North Chicago, United States
4 AbbVie Inc., North Chicago, United States
5 AbbVie Inc., North Chicago, United States
6 AbbVie Inc., North Chicago, United States
7 AbbVie Inc., North Chicago, United States
8 Genmab, Plainsboro, United States
9 AbbVie Inc., North Chicago, United States
10 AbbVie Inc., North Chicago, United States

Background

CD20, encoded by the MS4A1 gene, is an established target in non-Hodgkin lymphomas, including follicular lymphoma (FL) and diffuse large B cell lymphoma (DLBCL). In normal B cells and B-cell malignancies, CD20 expression is regulated by several mechanisms including MS4A1 5′UTR splicing. Four distinct transcript variants (V1–V4) have been identified, each with different ribosome accessibility and, therefore, differential translational efficiency and protein expression. A previous study showed that V1 and V3 represented the bulk of MS4A1 transcripts in samples from patients with FL and DLBCL (Ang Blood 2023). In vitro, expression of the translation-deficient V1 variant was associated with decreased activity of the CD3xCD20 T-cell engager (TCE) mosunetuzumab (mosun) while CD20-directed chimeric antigen receptor T-cell (CAR-T) activity was not affected, raising a question around the level of CD20 expression required for TCE activity. Herein, we assessed the response of isogenic tumor cell lines expressing different MS4A1 5’UTR splice variants to two CD3×CD20 TCEs, mosun, which is approved globally as 3L+ treatment for FL and in Japan with polatuzumab as 2L+ treatment for DLBCL, and epcoritamab (epcor), which is approved globally as 3L+ treatment for DLBCL and FL and with rituximab and lenalidomide as 2L+ treatment for FL, to establish the ability of TCEs to redirect cytotoxicity in a variant-specific setting.

Methods

MS4A1 constructs with V1 (translation defective) and V3 (translation productive) 5’UTRs and 3x-FLAG-HiBit were stably expressed in CD20-knockout SU-DHL-4 cells via lentiviral transduction. Pan CD20 and 5′UTR variants were quantified by isoform-specific RT-qPCR. CD20 protein expression was assessed by flow cytometry (surface expression), capillary electrophoresis (cell lysates), HiBiT:LgBiT lytic assay (cell lysates), and IHC. T-cell redirected cytotoxicity and activation were assessed using PBMC effector cells from six healthy donors across a clinically-relevant range of TCE concentrations (0.0001–10 µg/mL). Binding intensity of fluorescently labeled epcor and mosun was quantified on purified T cells and CD20+ SU-DHL-4 cells.

Results

In vitro, 7 lymphoma cell lines showed a strong correlation between surface CD20 protein and V3 MS4A1 mRNA expression (R2=0.86) while the correlation was lower for V1 (R2=0.42), an observation consistent with reduced translational competency. V2 and V4 were low or undetectable in all cell lines, as shown previously in normal B-cells and samples from patients with DLBCL and FL.

In CD20KO SU-DHL-4 cells reconstituted with MS4A1 splice variants, the V3 isoform drove high CD20 protein expression as detected by all methods while expression from the V1 isoform was undetectable by IHC and present at very low levels by capillary electrophoresis and HiBiT:LgBiT quantification. Both epcor and mosun induced dose-dependent cytotoxicity and T-cell activation in V3-expressing SU-DHL-4 cells. Epcor achieved 100% and 85% maximal killing in V3- and V1-expressing cells with EC50s of 0.001 and 0.37 µg/mL, respectively. Mosun also achieved 100% maximal killing in V3 cells but with 25-fold lower potency than epcor (EC50 0.025 µg/mL) and exhibited limited cytotoxicity in V1 cells with a 30% maximal killing at the highest concentration of 10 µg/mL.

Higher CD25+ CD8+ T-cell activation was observed in T cells co-cultured with cell lines expressing the V3 isoform than the V1 isoform, and epcor induced greater T-cell activation than mosun across doses. Binding to CD20 and CD3 was lower for mosun than epcor; at the clinically relevant concentration of 1 µg/mL, epcor binding was ~10-fold higher on V3-expressing SU-DHL-4 tumor cells and ~8-fold higher on T cells than mosun as measured by mean fluorescence intensity.

Conclusions

Here we show that, at concentrations spanning the Cmax of both TCEs, epcoritamab exhibited stronger CD3 and CD20 binding than mosunetuzumab and effectively redirected activity against both the V3 (high CD20) and V1 (low CD20) variant-expressing tumor cell lines. In contrast, mosunetuzumab showed detectable but lower binding to CD3 and CD20, which may have contributed to the limited T-cell activation and low cytotoxicity observed, particularly in the V1/low CD20-expressing cell line. These assessments demonstrate that epcoritamab has greater anti-tumor activity over mosunetuzumab in vitro across a broad range of CD20 expression levels, which could translate to a benefit for patients.

Devika Ashok: AbbVie Inc. - Stock (publicly traded); AbbVie Inc. - Current Employment